Sweden· SE-20211026000040
Octreotide Abacus Medicine 30 mg Pulver och vätska till injektionsvätska, depotsuspension
A octreotide product, registered in Sweden by Abacus Medicine A/S. The same ATC class is registered in 17 of our 19 countries.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
Where it is registered
Octreotide is registered in 17 of 19 countries.
Countries holding a registration under ATC H01CB02 (octreotide), each read from that country’s own register.
- This record: Sweden, from Swedish Medical Products Agency (Sweden)
- 10 of them publish a price we can compare per daily dose
Octreotide · ATC H01CB02
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of octreotide costs, country by country.
Normalised to the WHO defined daily dose (0.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Octreotide · price per daily dose (0.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$41.46
The record
At a glance
Swedish Medical Products Agency (Sweden)- Manufacturer
- Abacus Medicine A/S
- Country
- Sweden (SE)
- ATC code
- H01CB02
- ATC class
- Octreotide
- Defined daily dose
- 0.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20211026000040
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
367 interactions on record for octreotide.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Octreotide · interactions on record
367 records
- 4 severe
- 151 moderate
- 4 minor
- 168 info
Most severe, free to view
- LonafarnibA16AX20severe
- PexidartinibL01EX15severe
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
40 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under H01CB02
Octreotide, as other registers publish it.
- United StatesBYNFEZIA PenSun Pharmaceutical Industries, Inc.
- IrelandEzetimibe/Simvastatin Teva Pharma 10 mg/20 mg tabletsTeva B.V.
- IrelandEzetimibe/Simvastatin Teva Pharma 10 mg/80 mg tabletsTeva B.V.
- FinlandMycapssaAmryt Pharmaceuticals DAC
- United StatesMycapssaChiesi USA, Inc.
- United StatesMycapssaAmryt Pharmaceuticals Designated Activity Company
- PolandMycapssaAmryt Pharmaceuticals DAC
- BelgiumMycapssa 20 mgAmryt Pharmaceuticals DAC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d2f5c940-cf9a-473c-816c-ae5e7825f03f GET /v1/drugs/d2f5c940-cf9a-473c-816c-ae5e7825f03f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"PL"
],
"se_npl_id": "20211026000040",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20211026000040",
"product_doc_link": "https://docetp.mpa.se/LMF/Octreotide%20Abacus%20Medicine%2010%20mg%2020%20mg%2030%20mg%20powder%20and%20solvent%20for%20prolonged-release%20suspension%20for%20injection%20PL%20PL_09001bee83bc9a9a.pdf"
}See everything about octreotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.